Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345447 | 0.82 | ALDH1A1 (0.60) | CA12CA1CA2CA9CA14 | |
| SCHEMBL109451 | 0.81 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL24514067 | 0.80 | SLC7A5 (0.44) | STAT3RAB9AF2TMPRSS6 | |
| SCHEMBL18025996 | 0.80 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2344970 | 0.80 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2830738 | 0.79 | CYP17A1 (0.50) | CA12CA1CA9MAPTSMN1; SMN2 | |
| SCHEMBL1272206 | 0.79 | CA1 (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23139562 | 0.79 | CA12 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7287673 | 0.78 | CA1 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7346788 | 0.77 | CA1 (0.59) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4284798-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022164934-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022122035-A1 | COAGULATION FACTOR XIA INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021057818-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2017023992-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | CA12 1371/4885CA1 144/4885CA2 124/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | CA12 4802/4885CA1 4281/4885CA2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.